Rivaroxaban plasma levels in acute ischemic ...
Type de document :
Article dans une revue scientifique: Article original
DOI :
PMID :
URL permanente :
Titre :
Rivaroxaban plasma levels in acute ischemic stroke and intracerebral hemorrhage
Auteur(s) :
Seiffge, David J. [Auteur]
Kagi, Georg [Auteur]
Michel, Patrik [Auteur]
Fischer, Urs [Auteur]
Bejot, Yannick [Auteur]
Wegener, Susanne [Auteur]
Zedde, Marialuisa [Auteur]
Turc, Guillaume [Auteur]
Cordonnier, Charlotte [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Sandor, Peter S. [Auteur]
Rodier, Gilles [Auteur]
Zini, Andrea [Auteur]
Cappellari, Manuel [Auteur]
Schadelin, Sabine [Auteur]
Polymeris, Alexandros A. [Auteur]
Werring, David J. [Auteur]
Thilemann, Sebastian [Auteur]
Maestrini, Ilaria [Auteur]
Berge, Eivind [Auteur]
Traenka, Christopher [Auteur]
Vehoff, Jochen [Auteur]
De Marchis, Gian Marco [Auteur]
Kapauer, Monika [Auteur]
Peters, Nils [Auteur]
Sirimarco, Gaia [Auteur]
Bonati, Leo H. [Auteur]
Arnold, Marcel [Auteur]
Lyrer, Philippe A. [Auteur]
De Maistre, Emmanuel [Auteur]
Luft, Andreas [Auteur]
Tsakiris, Dimtrios A. [Auteur]
Engelter, Stefan T. [Auteur]
Kagi, Georg [Auteur]
Michel, Patrik [Auteur]
Fischer, Urs [Auteur]
Bejot, Yannick [Auteur]
Wegener, Susanne [Auteur]
Zedde, Marialuisa [Auteur]
Turc, Guillaume [Auteur]
Cordonnier, Charlotte [Auteur]
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Troubles cognitifs dégénératifs et vasculaires - U1171
Troubles cognitifs dégénératifs et vasculaires - U 1171 - EA 1046 [TCDV]
Sandor, Peter S. [Auteur]
Rodier, Gilles [Auteur]
Zini, Andrea [Auteur]
Cappellari, Manuel [Auteur]
Schadelin, Sabine [Auteur]
Polymeris, Alexandros A. [Auteur]
Werring, David J. [Auteur]
Thilemann, Sebastian [Auteur]
Maestrini, Ilaria [Auteur]
Berge, Eivind [Auteur]
Traenka, Christopher [Auteur]
Vehoff, Jochen [Auteur]
De Marchis, Gian Marco [Auteur]
Kapauer, Monika [Auteur]
Peters, Nils [Auteur]
Sirimarco, Gaia [Auteur]
Bonati, Leo H. [Auteur]
Arnold, Marcel [Auteur]
Lyrer, Philippe A. [Auteur]
De Maistre, Emmanuel [Auteur]
Luft, Andreas [Auteur]
Tsakiris, Dimtrios A. [Auteur]
Engelter, Stefan T. [Auteur]
Titre de la revue :
Annals of neurology
Nom court de la revue :
Ann. Neurol.
Date de publication :
2018-02-02
ISSN :
1531-8249
Discipline(s) HAL :
Sciences du Vivant [q-bio]
Résumé en anglais : [en]
Information about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban.
In a multicenter registry-based study ...
Lire la suite >Information about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. In a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev ≤ 100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev ≥ 75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. Among 241 patients (median age = 80 years, interquartile range [IQR] = 73-84; median time from onset to admission = 2 hours, IQR = 1-4.5 hours; median RivLev = 89ng/ml, IQR = 31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR = 30-202) and ICH patients (102ng/ml, IQR = 51-165; p = 0.24). Trough RivLev(≤137ng/ml) RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459.Lire moins >
Lire la suite >Information about rivaroxaban plasma level (RivLev) may guide treatment decisions in patients with acute ischemic stroke (AIS) and intracerebral hemorrhage (ICH) taking rivaroxaban. In a multicenter registry-based study (Novel Oral Anticoagulants in Stroke Patients collaboration; ClinicalTrials.gov: NCT02353585) of patients with stroke while taking rivaroxaban, we compared RivLev in patients with AIS and ICH. We determined how many AIS patients had RivLev ≤ 100ng/ml, indicating possible eligibility for thrombolysis, and how many ICH patients had RivLev ≥ 75ng/ml, making them possibly eligible for the use of specific reversal agents. We explored factors associated with RivLev (Spearman correlation, regression models) and studied the sensitivity and specificity of international normalized ratio (INR) thresholds to substitute RivLev using cross tables and receiver operating characteristic curves. Among 241 patients (median age = 80 years, interquartile range [IQR] = 73-84; median time from onset to admission = 2 hours, IQR = 1-4.5 hours; median RivLev = 89ng/ml, IQR = 31-194), 190 had AIS and 51 had ICH. RivLev was similar in AIS patients (82ng/ml, IQR = 30-202) and ICH patients (102ng/ml, IQR = 51-165; p = 0.24). Trough RivLev(≤137ng/ml) RivLev did not differ between patients with AIS and ICH. Half of the patients with AIS under rivaroxaban had a RivLev low enough to consider thrombolysis. In ICH patients, two-thirds had a RivLev high enough to meet the eligibility for the use of a specific reversal agent. INR thresholds perform poorly to inform treatment decisions in individual patients. Ann Neurol 2018;83:451-459.Lire moins >
Langue :
Anglais
Audience :
Internationale
Vulgarisation :
Non
Établissement(s) :
CHU Lille
CNRS
Inserm
Université de Lille
CNRS
Inserm
Université de Lille
Collections :
Équipe(s) de recherche :
Troubles cognitifs dégénératifs et vasculaires
Date de dépôt :
2019-11-27T14:32:08Z